


Furegrelate

Cat. No.:	HY-106080
CAS No.:	85666-24-6
Molecular Formula:	C ₁₅ H ₁₁ NO ₃
Molecular Weight:	253.25
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC ₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent ^{[1][2]} .
In Vivo	Furegrelate (1-5 mg/kg; po) prevents blockage of the coronary artery ^[1] . Furegrelate (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation ^[1] . Furegrelate blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature ^[2] . Furegrelate has a long half-life compared to several other drugs used to treat PAH, including nitric oxide and prostaglyclin analogues; And Furegrelate is highly specific to the target enzyme ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42.

[2]. Hirehallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA